Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

This study has been completed.
Information provided by (Responsible Party):
Nanotherapeutics, Inc. Identifier:
First received: April 13, 2009
Last updated: April 11, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2009
  Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)